​
	How Gene Editing Can Help Lead to a Cure (Part Two), and the 2017 Nobel Prizes for Science In Part Two of his look at the gene-editing technology known as CRISPR, IMF Chairman Dr. Brian Durie examines its impact on the future of myeloma treatment. Immunotherapy and molecular biology assessment are the most fertile areas for the applications of this exciting approach, he says. “The sky is the limit.” Also, the science behind the 2017 Nobel Prizes in science. Read Dr. Durie’s blog.
	Tickets Selling Fast: Star-Studded 11th Annual IMF Comedy Celebration Have you heard about the star-studded lineup for the IMF 11th Annual Comedy Celebration on Saturday, November 4, 2017, at the Wilshire Ebell Theatre in Los Angeles? Actor and comedian Ray Romano returns to host an unforgettable evening of comedy that will feature performers including Hannibal Buress, Rachel Feinstein, Nikki Glaser, Robert Klein, Marc Maron, Kumail Nanjiani, Iliza Shlesinger, and Fred Willard. Tickets are selling fast so get yours now!​
	Darzalex (daratumumab) Approved in Japan for Treatment of Relapsed or Refractory Multiple Myeloma On September 27, 2017, the Japanese Ministry of Health, Labor, and Welfare approved Darzalex® (daratumumab) in combination with either Revlimid® (lenalidomide) and dexamethasone, or Velcade (bortezomib) and dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma.
	IMF Nurse Leadership Board Authors ‘Multiple Myeloma’ Supplement for the Clinical Journal of Oncology Nursing The IMF’s Nurse Leadership Board authored the October 2017 Clinical Journal of Oncology Nursing’s “Myeloma Supplement.” This supplement includes articles on distress, fatigue, and sexuality; symptom-management for renal, GI, and peripheral nerve issues; bone health, pain, and mobility; heart and lung complications; myelosuppression; and more. Nurses may complete related activities with each article to receive CNE-credit. Learn more about each article.
	Patient & Family Seminar in Madrid Empowered Patients! The 2nd IMF and CEMMP (Comunidad Española de Pacientes con Mieloma Múltiple) Patient & Family Seminar was held in Madrid, Spain, on September 14, 2017. Teresa Regueiro López, the Founder and President of CEMPP, assembled myeloma experts from Madrid, Navarra, Barcelona, and other cities to educate patients about best treatment options available in Spain.120 patients and caregivers attended the seminar that included in-depth question-and-answer sessions. Seminar topics included recent drug approvals, the importance of clinical trials, and treatment innovations. The IMF and the Spanish myeloma community look forward to next year’s seminars in Madrid and Barcelona.
	What do you recommend if a patient experiences fatigue on the combination of Revlimid, Darzalex, and dexamethasone? In this week’s video, Is Kyprolis® (carfilzomib) a treatment option for a first relapse of myeloma?

This weekly newsletter is supported from funds by donors like you. Donate to continue to make publications like this one possible.

​

We Thank Our Sponsors: Amgen, Celgene Corporation, Genentech, Janssen Oncology, and Takeda Oncology